pioglitazone has been researched along with Disbacteriosis in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems." | 2.82 | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. ( Benfari, G; Bonapace, S; Byrne, CD; Mantovani, A; Simon, TG; Targher, G, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mantovani, A | 1 |
| Byrne, CD | 1 |
| Benfari, G | 1 |
| Bonapace, S | 1 |
| Simon, TG | 1 |
| Targher, G | 1 |
| Li, JM | 1 |
| Yu, R | 1 |
| Zhang, LP | 1 |
| Wen, SY | 1 |
| Wang, SJ | 1 |
| Zhang, XY | 1 |
| Xu, Q | 1 |
| Kong, LD | 1 |
1 review available for pioglitazone and Disbacteriosis
| Article | Year |
|---|---|
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.
Topics: Bariatric Surgery; Dysbiosis; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypoglycemic | 2022 |
1 other study available for pioglitazone and Disbacteriosis
| Article | Year |
|---|---|
Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: a benefit of short-chain fatty acids.
Topics: Animals; Doublecortin Protein; Dysbiosis; Fatty Acids, Volatile; Fructose; Gastrointestinal Microbio | 2019 |